Company intelligence / Profile preview

LXO US

San Francisco, California, United States

Ownership: Private
Development stage: Other

Overview

LXO is an early-stage biotechnology company focused on developing novel small molecule inhibitors targeting the lysyl oxidase (LOX) family of enzymes. These enzymes play a critical role in the remodeling of the extracellular matrix, which is a key driver in both fibrotic diseases and the progression of various solid tumors. By inhibiting LOX, the company aims to disrupt the structural integrity of the tumor microenvironment and reduce tissue stiffness associated with fibrosis. LXO's research is currently in the pre-clinical phase, with a primary focus on oncology and respiratory or hepatic fibrotic conditions.

Therapeutic areas: OncologyOther
Modalities: Small molecule
Industry: Biotech

Beyond the preview

Go deeper on LXO US.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on LXO US.

Explore the full profile